DURHAM, N.C. & SEATTLE-- November 13, 2023--Pioneering epigenome editing company Tune Therapeutics has announced it is working on a new and potentially curative approach to treating chronic HBV infection. The...
Arthur Klausner will be a panelist at "The Venture Prognosis - what's driving investment preferences?" at the Life Sciences & Healthcare Venture Summit on October 23, 2007 in NYC
News | 10. 23. 2007
